acromegaly

BIM-23190 aceate, a somatostatin analog, a selective agonist of SSTR2 and SSTR5. BIM-23190 can be used in cancer and acromegaly studies.

Pasireotide (SOM230) acetate is a long-acting cyclohexapeptide growth hormone inhibitory hormone analog with antisecretory, antiproliferative, and proapoptotic activities.Pasireotide (SOM230) acetate inhibits the secretion of GH, IGF-I, and ACTH, and can be used in the study of acromegaly and Cushing's disease. Pasireotide (SOM230) acetate also enhances the agonist activity of growth inhibitory receptors, with pKi of 8.2, 9.0, 9.1, <7.0 and 9.9 for sst1, 2, 3, 4 and 5, respectively.

Octreotide (SMS 201-995) is a potent inhibitor of growth hormone, glucagon, and insulin.

BIM-23190 is a somatostatin analog that acts as a selective agonist for SSTR2 and SSTR5 receptors. It displays potency with K i values of 0.34 nM and 11.1 nM for SSTR2 and SSTR5, respectively. BIM-23190 finds utility in cancer and acromegaly research.

BIM-23190 hydrochloride, a selective agonist for somatostatin receptors SSTR2 and SSTR5 with Ki values of 0.34 nM and 11.1 nM respectively, is a somatostatin analog utilized in research on cancer and acromegaly[1][3].

Lanreotide, a somatostatin analogue, suppresses GH/IGF-I hypersecretion in acromegaly patients. It also used to manage neuroendocrine tumours.